M&A Deal Summary

Selvita Acquires Fidelta

On November 23, 2020, Selvita acquired life science company Fidelta from Galapagos for 31M EUR

Acquisition Highlights
  • This is Selvita’s 1st transaction in the Life Science sector.
  • This is Selvita’s largest (disclosed) transaction.
  • This is Selvita’s 1st transaction in Croatia.

M&A Deal Summary
Date 2020-11-23
Target Fidelta
Sector Life Science
Buyer(s) Selvita
Sellers(s) Galapagos
Deal Type Divestiture
Deal Value 31M EUR

Target

Fidelta

Zagreb, Croatia
Fidelta Ltd. is a drug discovery service company with core scientific competencies in inflammation, fibrosis, and anti-infectives. The scope of services provided by Fidelta is complementary to Selvita’s offerings and will enable Selvita to build a competitive advantage in business areas such as DMPK, in vivo pharmacology, and toxicology, as well as increase its scale of operations within medicinal chemistry and in vitro pharmacology. Fidelta is based in Zagreb, Croatia.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Selvita

Krakow, Poland
Category Company
Founded 2007
Sector Life Science
Employees387
Revenue 347M PLN (2023)
DESCRIPTION

Selvita is an integrated service company providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development. Selvita was founded in 2007 and is based in Krakow, Poland.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 1
Country (Croatia) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-27 PozLab

Poznan, Poland

PozLab is a contract development and manufacturing organization (“CDMO”) offering expert drug product development services and small pilot plant capabilities. The company provides drug product services through dedicated analytical, formulation, and process development, followed by analytical and microbiological testing, including the analysis of APIs and excipients. PozLab is based in Poznan, Poland.

Buy -

Seller(S) 1

SELLER

Galapagos

Mechelen, Belgium
Category Company
Founded 1999
Sector Life Science
Employees683
Revenue 240M EUR (2023)
DESCRIPTION

Galapagos is a clinical stage biotech company focused on developing novel mode of action medicines. Galapagos was incorporated in 1999 and is based in Mechelen, Belgium.

DEAL STATS #
Overall 4 of 4
Sector (Life Science) 4 of 4
Type (Divestiture) 4 of 4
Country (Croatia) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-03-31 Argenta Discovery 2009

Harlow, United Kingdom

Argenta Discovery 2009 Ltd. is a drug discovery company.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-22 CellPoint

Oegstgeest, Netherlands

CellPoint is a developer of proprietary xCellit real-time monitoring software system, generating clinical data to validate decentralized manufacturing supply model with CD19 CAR-T for rrNHL/rrCLL. CellPoint is based in Oegstgeest, Netherlands.

Buy $125M
Mergr

Product

Company

Legal